Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Senores PharmaceuticalsNSE:SENORES -3.49%21 3-1 Month Momentum % is 15.16% as of Sep. 16, 2026. GuruFocus rates NSE:SENORES with a GF Score™ of 21/100. The stock has 7 warning signs investors should review. Among 1,017 Drug Manufacturers companies, Senores Pharmaceuticals ranks better than 79.35% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-16), Senores Pharmaceuticals's 3-1 Month Momentum % is 15.16%.
The industry rank for Senores Pharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:
NSE:SENORES's 3-1 Month Momentum % is ranked better than 79.35% of 1017
companies
in the Drug Manufacturers industry
Industry Median: 1.86
vs NSE:SENORES: 15.16
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Senores Pharmaceuticals 3-1 Month Momentum % Related Terms
NSE:SENORES vs LLY, JNJ, ABBV: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - General subindustry, Senores Pharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senores Pharmaceuticals 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Senores Pharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Senores Pharmaceuticals's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senores Pharmaceuticals (NSE:SENORES) has a 3-1 Month Momentum % of 15.16% as of Sep. 16, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Senores Pharmaceuticals and its competitors. According to the industry distribution chart, Senores Pharmaceuticals ranks #210 out of 1017 companies in the Drug Manufacturers industry, placing it in the top 20.6%.
Is Senores Pharmaceuticals' 3-1 Month Momentum % too high?
Senores Pharmaceuticals' current 3-1 Month Momentum % is 15.16%. The Drug Manufacturers industry median 3-1 Month Momentum % is 1.86. Senores Pharmaceuticals' value of 15.16% is 715.1% above this industry median. Based on the distribution chart, Senores Pharmaceuticals ranks #210 out of 1017 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Senores Pharmaceuticals has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Senores Pharmaceuticals' 3-1 Month Momentum % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Senores Pharmaceuticals ranks #210 out of 1017 companies for 3-1 Month Momentum %. This places Senores Pharmaceuticals in the top 21% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 1.86. Senores Pharmaceuticals' value of 15.16% is 715.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
The median 3-1 Month Momentum % among Drug Manufacturers companies is 1.86, based on 1,017 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Senores Pharmaceuticals's current 3-1 Month Momentum % of 15.16% is 715.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Senores Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-1 Month Momentum % is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Senores Pharmaceuticals's current 3-1 Month Momentum % is 15.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senores Pharmaceuticals stock overvalued right now?
Senores Pharmaceuticals (NSE:SENORES) has a current 3-1 Month Momentum % of 15.16%. The current 3-1 Month Momentum % is 15.16% and 715.1% above the Drug Manufacturers industry median of 1.86. Senores Pharmaceuticals' overall GF Score™ is 21/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Senores Pharmaceuticals (NSE:SENORES), the current 3-1 Month Momentum % is 15.16% as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Senores Pharmaceuticals Ltd is a research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of the USA, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing the company as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, It strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.
21GF Score
Get the complete analysis for NSE:SENORES
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SENORES has been successfully added to your 
